Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.
Identifieur interne : 000309 ( Main/Exploration ); précédent : 000308; suivant : 000310Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.
Auteurs : J. Delangue [France] ; N. Salez ; L. Ninove ; A. Kieffer ; C. Zandotti ; M. Seston ; B. Lina ; A. Nougairede ; R. Charrel ; A. Flahault ; X. De LamballerieSource :
- Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases [ 1469-0691 ] ; 2012.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Anticorps antiviraux (sang), Anticorps neutralisants (sang), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Facteurs âges (MeSH), Femelle (MeSH), France (épidémiologie), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Nourrisson (MeSH), Nouveau-né (MeSH), Pandémies (MeSH), Population urbaine (MeSH), Réactions croisées (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Tests d'inhibition de l'hémagglutination (MeSH), Tests de neutralisation (MeSH), Études séroépidémiologiques (MeSH).
- MESH :
- immunologie : Sous-type H1N1 du virus de la grippe A.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- virologie : Grippe humaine.
- épidémiologie : France, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Facteurs âges, Femelle, Humains, Jeune adulte, Mâle, Nourrisson, Nouveau-né, Pandémies, Population urbaine, Réactions croisées, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Tests de neutralisation, Études séroépidémiologiques.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Age Factors (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Child (MeSH), Child, Preschool (MeSH), Cross Reactions (MeSH), Female (MeSH), France (epidemiology), Hemagglutination Inhibition Tests (MeSH), Humans (MeSH), Infant (MeSH), Infant, Newborn (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza, Human (epidemiology), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Neutralization Tests (MeSH), Pandemics (MeSH), Seroepidemiologic Studies (MeSH), Urban Population (MeSH), Young Adult (MeSH).
- MESH :
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- geographic , epidemiology : France.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype.
- virology : Influenza, Human.
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Cross Reactions, Female, Hemagglutination Inhibition Tests, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neutralization Tests, Pandemics, Seroepidemiologic Studies, Urban Population, Young Adult.
Abstract
We looked for evidence of antibodies to the 2009 influenza A/H1N1 pandemic virus in panels of sera from individuals living in metropolitan France, obtained either before, during or after the epidemic, using standard haemagglutination inhibition and microneutralization tests. The difference between seroprevalence values measured in post- and pre-epidemic panels was used as an estimate of seroconversion rate in different age groups (23.4% (0-24 years, age-group 0); 16.5% (25-34); 7.9% (35-44); 7.2% (45-54); 1.6% (55-64); and 3.1% (>65)), confirming that the distribution of cases in different age groups was similar to that of the seasonal H1N1 virus. During the pre-pandemic period low-titre cross-reactive antibodies were present in a large proportion of the population (presumably acquired against seasonal H1N1) whereas cross-reactive antibodies were detected in individuals over the age of 65 years with significantly higher prevalence and serological titres (presumably acquired previously against Spanish flu-related H1N1 strains). Clinical data and analysis of post-pandemic seroprevalence showed that few of these latter patients were infected by the influenza virus during the epidemic. In contrast, the majority of both clinical cases and seroconversions were recorded in the 0-24 age group and a global inverse relationship between prevalence of antibodies to pH1N1 in the pre-pandemic period and rate of seroconversion was observed amongst age groups. Our results emphasize the complex relationships involved in antigenic reactivity to pandemic and seasonal H1N1 viral antigens; hence the difficulty in distinguishing between low-titre specific and cross-reactive antibodies, establishing precise seroprevalence numbers and fully understanding the relationship between previous immunity to seasonal viruses and protection against the novel variant.
DOI: 10.1111/j.1469-0691.2011.03545.x
PubMed: 21635661
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.</title><author><name sortKey="Delangue, J" sort="Delangue, J" uniqKey="Delangue J" first="J" last="Delangue">J. Delangue</name><affiliation wicri:level="3"><nlm:affiliation>Unité des Virus Emergents, UMR190 Université Aix-Marseille 2 and Institut de Recherche pour le Développement, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité des Virus Emergents, UMR190 Université Aix-Marseille 2 and Institut de Recherche pour le Développement, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Salez, N" sort="Salez, N" uniqKey="Salez N" first="N" last="Salez">N. Salez</name></author><author><name sortKey="Ninove, L" sort="Ninove, L" uniqKey="Ninove L" first="L" last="Ninove">L. Ninove</name></author><author><name sortKey="Kieffer, A" sort="Kieffer, A" uniqKey="Kieffer A" first="A" last="Kieffer">A. Kieffer</name></author><author><name sortKey="Zandotti, C" sort="Zandotti, C" uniqKey="Zandotti C" first="C" last="Zandotti">C. Zandotti</name></author><author><name sortKey="Seston, M" sort="Seston, M" uniqKey="Seston M" first="M" last="Seston">M. Seston</name></author><author><name sortKey="Lina, B" sort="Lina, B" uniqKey="Lina B" first="B" last="Lina">B. Lina</name></author><author><name sortKey="Nougairede, A" sort="Nougairede, A" uniqKey="Nougairede A" first="A" last="Nougairede">A. Nougairede</name></author><author><name sortKey="Charrel, R" sort="Charrel, R" uniqKey="Charrel R" first="R" last="Charrel">R. Charrel</name></author><author><name sortKey="Flahault, A" sort="Flahault, A" uniqKey="Flahault A" first="A" last="Flahault">A. Flahault</name></author><author><name sortKey="De Lamballerie, X" sort="De Lamballerie, X" uniqKey="De Lamballerie X" first="X" last="De Lamballerie">X. De Lamballerie</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:21635661</idno><idno type="pmid">21635661</idno><idno type="doi">10.1111/j.1469-0691.2011.03545.x</idno><idno type="wicri:Area/Main/Corpus">000365</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000365</idno><idno type="wicri:Area/Main/Curation">000365</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000365</idno><idno type="wicri:Area/Main/Exploration">000365</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.</title><author><name sortKey="Delangue, J" sort="Delangue, J" uniqKey="Delangue J" first="J" last="Delangue">J. Delangue</name><affiliation wicri:level="3"><nlm:affiliation>Unité des Virus Emergents, UMR190 Université Aix-Marseille 2 and Institut de Recherche pour le Développement, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité des Virus Emergents, UMR190 Université Aix-Marseille 2 and Institut de Recherche pour le Développement, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Salez, N" sort="Salez, N" uniqKey="Salez N" first="N" last="Salez">N. Salez</name></author><author><name sortKey="Ninove, L" sort="Ninove, L" uniqKey="Ninove L" first="L" last="Ninove">L. Ninove</name></author><author><name sortKey="Kieffer, A" sort="Kieffer, A" uniqKey="Kieffer A" first="A" last="Kieffer">A. Kieffer</name></author><author><name sortKey="Zandotti, C" sort="Zandotti, C" uniqKey="Zandotti C" first="C" last="Zandotti">C. Zandotti</name></author><author><name sortKey="Seston, M" sort="Seston, M" uniqKey="Seston M" first="M" last="Seston">M. Seston</name></author><author><name sortKey="Lina, B" sort="Lina, B" uniqKey="Lina B" first="B" last="Lina">B. Lina</name></author><author><name sortKey="Nougairede, A" sort="Nougairede, A" uniqKey="Nougairede A" first="A" last="Nougairede">A. Nougairede</name></author><author><name sortKey="Charrel, R" sort="Charrel, R" uniqKey="Charrel R" first="R" last="Charrel">R. Charrel</name></author><author><name sortKey="Flahault, A" sort="Flahault, A" uniqKey="Flahault A" first="A" last="Flahault">A. Flahault</name></author><author><name sortKey="De Lamballerie, X" sort="De Lamballerie, X" uniqKey="De Lamballerie X" first="X" last="De Lamballerie">X. De Lamballerie</name></author></analytic><series><title level="j">Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</title><idno type="eISSN">1469-0691</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Age Factors (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Cross Reactions (MeSH)</term><term>Female (MeSH)</term><term>France (epidemiology)</term><term>Hemagglutination Inhibition Tests (MeSH)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Infant, Newborn (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (virology)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Neutralization Tests (MeSH)</term><term>Pandemics (MeSH)</term><term>Seroepidemiologic Studies (MeSH)</term><term>Urban Population (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (sang)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Facteurs âges (MeSH)</term><term>Femelle (MeSH)</term><term>France (épidémiologie)</term><term>Grippe humaine (virologie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Nouveau-né (MeSH)</term><term>Pandémies (MeSH)</term><term>Population urbaine (MeSH)</term><term>Réactions croisées (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Tests d'inhibition de l'hémagglutination (MeSH)</term><term>Tests de neutralisation (MeSH)</term><term>Études séroépidémiologiques (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>France</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Cross Reactions</term><term>Female</term><term>Hemagglutination Inhibition Tests</term><term>Humans</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Middle Aged</term><term>Neutralization Tests</term><term>Pandemics</term><term>Seroepidemiologic Studies</term><term>Urban Population</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs âges</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Nourrisson</term><term>Nouveau-né</term><term>Pandémies</term><term>Population urbaine</term><term>Réactions croisées</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests d'inhibition de l'hémagglutination</term><term>Tests de neutralisation</term><term>Études séroépidémiologiques</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We looked for evidence of antibodies to the 2009 influenza A/H1N1 pandemic virus in panels of sera from individuals living in metropolitan France, obtained either before, during or after the epidemic, using standard haemagglutination inhibition and microneutralization tests. The difference between seroprevalence values measured in post- and pre-epidemic panels was used as an estimate of seroconversion rate in different age groups (23.4% (0-24 years, age-group 0); 16.5% (25-34); 7.9% (35-44); 7.2% (45-54); 1.6% (55-64); and 3.1% (>65)), confirming that the distribution of cases in different age groups was similar to that of the seasonal H1N1 virus. During the pre-pandemic period low-titre cross-reactive antibodies were present in a large proportion of the population (presumably acquired against seasonal H1N1) whereas cross-reactive antibodies were detected in individuals over the age of 65 years with significantly higher prevalence and serological titres (presumably acquired previously against Spanish flu-related H1N1 strains). Clinical data and analysis of post-pandemic seroprevalence showed that few of these latter patients were infected by the influenza virus during the epidemic. In contrast, the majority of both clinical cases and seroconversions were recorded in the 0-24 age group and a global inverse relationship between prevalence of antibodies to pH1N1 in the pre-pandemic period and rate of seroconversion was observed amongst age groups. Our results emphasize the complex relationships involved in antigenic reactivity to pandemic and seasonal H1N1 viral antigens; hence the difficulty in distinguishing between low-titre specific and cross-reactive antibodies, establishing precise seroprevalence numbers and fully understanding the relationship between previous immunity to seasonal viruses and protection against the novel variant.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21635661</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2012</Year><Month>01</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-0691</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</Title><ISOAbbreviation>Clin. Microbiol. Infect.</ISOAbbreviation></Journal><ArticleTitle>Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.</ArticleTitle><Pagination><MedlinePgn>177-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1469-0691.2011.03545.x</ELocationID><Abstract><AbstractText>We looked for evidence of antibodies to the 2009 influenza A/H1N1 pandemic virus in panels of sera from individuals living in metropolitan France, obtained either before, during or after the epidemic, using standard haemagglutination inhibition and microneutralization tests. The difference between seroprevalence values measured in post- and pre-epidemic panels was used as an estimate of seroconversion rate in different age groups (23.4% (0-24 years, age-group 0); 16.5% (25-34); 7.9% (35-44); 7.2% (45-54); 1.6% (55-64); and 3.1% (>65)), confirming that the distribution of cases in different age groups was similar to that of the seasonal H1N1 virus. During the pre-pandemic period low-titre cross-reactive antibodies were present in a large proportion of the population (presumably acquired against seasonal H1N1) whereas cross-reactive antibodies were detected in individuals over the age of 65 years with significantly higher prevalence and serological titres (presumably acquired previously against Spanish flu-related H1N1 strains). Clinical data and analysis of post-pandemic seroprevalence showed that few of these latter patients were infected by the influenza virus during the epidemic. In contrast, the majority of both clinical cases and seroconversions were recorded in the 0-24 age group and a global inverse relationship between prevalence of antibodies to pH1N1 in the pre-pandemic period and rate of seroconversion was observed amongst age groups. Our results emphasize the complex relationships involved in antigenic reactivity to pandemic and seasonal H1N1 viral antigens; hence the difficulty in distinguishing between low-titre specific and cross-reactive antibodies, establishing precise seroprevalence numbers and fully understanding the relationship between previous immunity to seasonal viruses and protection against the novel variant.</AbstractText><CopyrightInformation>© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delangue</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unité des Virus Emergents, UMR190 Université Aix-Marseille 2 and Institut de Recherche pour le Développement, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salez</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ninove</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kieffer</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Zandotti</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Seston</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lina</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nougairede</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Charrel</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Flahault</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>de Lamballerie</LastName><ForeName>X</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Microbiol Infect</MedlineTA><NlmUniqueID>9516420</NlmUniqueID><ISSNLinking>1198-743X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="N">Urban Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21635661</ArticleId><ArticleId IdType="doi">10.1111/j.1469-0691.2011.03545.x</ArticleId><ArticleId IdType="pii">S1198-743X(14)61344-6</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Marseille</li></settlement></list><tree><noCountry><name sortKey="Charrel, R" sort="Charrel, R" uniqKey="Charrel R" first="R" last="Charrel">R. Charrel</name><name sortKey="De Lamballerie, X" sort="De Lamballerie, X" uniqKey="De Lamballerie X" first="X" last="De Lamballerie">X. De Lamballerie</name><name sortKey="Flahault, A" sort="Flahault, A" uniqKey="Flahault A" first="A" last="Flahault">A. Flahault</name><name sortKey="Kieffer, A" sort="Kieffer, A" uniqKey="Kieffer A" first="A" last="Kieffer">A. Kieffer</name><name sortKey="Lina, B" sort="Lina, B" uniqKey="Lina B" first="B" last="Lina">B. Lina</name><name sortKey="Ninove, L" sort="Ninove, L" uniqKey="Ninove L" first="L" last="Ninove">L. Ninove</name><name sortKey="Nougairede, A" sort="Nougairede, A" uniqKey="Nougairede A" first="A" last="Nougairede">A. Nougairede</name><name sortKey="Salez, N" sort="Salez, N" uniqKey="Salez N" first="N" last="Salez">N. Salez</name><name sortKey="Seston, M" sort="Seston, M" uniqKey="Seston M" first="M" last="Seston">M. Seston</name><name sortKey="Zandotti, C" sort="Zandotti, C" uniqKey="Zandotti C" first="C" last="Zandotti">C. Zandotti</name></noCountry><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Delangue, J" sort="Delangue, J" uniqKey="Delangue J" first="J" last="Delangue">J. Delangue</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000309 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000309 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21635661
|texte= Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21635661" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeFranceV1
| This area was generated with Dilib version V0.6.35. |  |